ArticleAmerican journal of cancer research2026
Effectiveness and safety of recombinant human endostatin injection plus immune checkpoint inhibitors for non-small cell lung cancer: a single-centered, retrospective study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the clinical effectiveness and safety of recombinant human endostatin (rh-Endo) injection plus immune checkpoint inhibitor (ICI) treatment of non-small cell lung cancer (NSCLC) treatment. We collected the medical records and follow-up data of inoperable NSCLC patients who received the corresponding anti-tumor treatment for at least 4 cycles and were discharged from our hospital from January 2021 to January 2023 for a retrospective analysis. According to the treatment methods, they were assigned to rh-Endo+ICIs (Endostatin+ICIs) and ICIs groups. Rh-Endo injection was administered at 210 mg each time via continuous chemotherapy pump infusion for 3 days, once every 3 weeks. The use of ICIs followed the instructions. Neither rh-Endo injection nor ICIs were allowed to be administered at a reduced dose. Therapeutic efficacy was compared between groups, tumor biomarkers, health status, and life quality were observed, and the occurrence of adverse reactions was documented. Progression-free survival (PFS) and overall survival (OS) during patient follow-up (2 years) were tracked. In this study, 114 eligible cases were included, with 73 receiving ICIs+rh-Endo. The disease control rate (DCR) of the ICIs and Endostatin+ICIs groups was 46.35% and 75.34% (P=0.002), respectively. Both cohorts exhibited reduced serum cytokeratin 19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCCA), carbohydrate antigen 50 (CA50) after three cycles of treatment, especially in the Endostatin+ICIs group (P<0.05). Endostatin+ICIs also contributed to better health status and life quality in patients compared to ICIs. The Endostatin+ICIs group displayed longer mean PFS (10.6 months vs. 6.8 months) and mean OS (17.6 months vs. 8.3 months) than the ICIs group. The results indicated that rh-Endo injection plus ICIs showesno significantly difference compare to ICIs alone in the adverse reaction rate, shows superior efficacy in improving clinical efficacy, significantly prolonging PFS and OS, and boosting patients' health status and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.